Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Teva Boosts CNS Portfolio With $3.2 Billion Purchase Of Auspex

Executive Summary

Novartis raises its game in immuno-oncology through Aduro collaboration, while Merck Serono partners up with a CAR-T program at Intrexon. UnitedHealth grows its PBM business by acquiring Catamaran; Horizon expands its orphan drug portfolio in buyout of Hyperion.

Advertisement

Related Content

Novartis Aims To Leap-Frog Into Next Immuno-Oncology Wave With Aduro
Evotec CEO: Growth Prospects Rely Heavily On Roche, Sanofi Deals
Rite Aid To Gain Specialty Drug, Part D Platforms With PBM EnvisionRx
Cigna Retains Formulary Management Control Under Contract With PBM Catamaran

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS056763

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel